Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
38 hedge funds and large institutions have $50.2M invested in Lumos Pharma, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 8 closing their positions.
11% less capital invested
Capital invested by funds: $56.8M → $50.2M (-$6.52M)
12% less funds holding
Funds holding: 43 → 38 (-5)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.6M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$282K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$82.2K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$62.6K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$39.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IFG
Investors Financial Group
Plymouth,
Minnesota
|
-$1.4M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$825K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$462K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$188K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$86K |
LUMO Hedge Fund Activity: Q3 2020 in Review
38 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2020, worth a combined $50.2M — down 11% from $56.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LUMO and 3 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $3.6M. The largest seller was Investors Financial Group, cutting an estimated $1.4M.
- 38 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2020, down from 43 in Q2 2020.
- Funds reported $50.2M of Lumos Pharma, Inc. Common Stock stock for Q3 2020, down 11% quarter-over-quarter.
- 3 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2020 and 8 closed out, a net change of -5 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2020 was Opaleye Management, an estimated $3.6M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2020 was Investors Financial Group, an estimated $1.4M sold.
Based on aggregated 13F filings for Q3 2020.